Tenon Medical Inc

Tenon Medical has closed its previously announced warrant inducement agreement with an institutional investor, bringing in gross cash proceeds of $2,872,338.58. The investor exercised outstanding warrants to purchase an aggregate of 572,179 shares of the company's common stock, and in return received new unregistered warrants to purchase up to 858,269 shares, equal to 150% of the shares issued in the exercise, at an exercise price of $5.02 per share. The new warrants are immediately exercisable and expire five years from issuance. The gross proceeds exclude any amounts that may be received upon exercise of the new warrants and are before deducting financial advisor fees and other expenses. WallachBeth Capital acted as financial advisor on the transaction, and Tenon has agreed to file a resale registration statement with the SEC covering the shares issuable upon exercise of the new warrants.

Tenon Medical reported second quarter revenue of $1.3 million, up 127% year over year, and gross profit of $0.8 million, up 232%, while outlining a cadence of sacropelvic product launches over the next six to nine months. The company received FDA 510(k) clearance for its Catamaran SI Joint Fusion System on July 2, with updated instruments expected to improve margins beginning in Q3. Tenon also closed a public offering on July 1 for gross proceeds of $4.2 million, adding to its $1.7 million cash position at quarter end. Management did not provide formal guidance but said an enhanced SImmetry+ system will become clinically active in Q3 and a novel posterior technology is being prepared for FDA submission.

Several biotech stocks posted sharp gains Monday, led by Tenon Medical after an S-1 filing, Nuvectis Pharma on a licensing deal with Haisco, and REGENXBIO on a regulatory reversal for its Hunter syndrome gene therapy. Tenon filed to offer up to 1.81 million shares and 6.98 million warrants at $0.6021 per unit, with shares closing up 77.57% at $0.62. Nuvectis announced exclusive ex-China rights to two clinical-stage compounds, NXP100 and NXP200, from Haisco Pharmaceutical Group, sending its stock up 19.61% to $16.53. REGENXBIO gained 16.28% to $9.07 after the FDA agreed that existing data for NAVSUNLI is sufficient for an accelerated approval resubmission, with a Type A meeting set for next month and BLA resubmission expected in the third quarter of 2026. Other notable movers included Azitra, up 33.95% after a shareholder letter outlined a 2026 roadmap for its cosmetic ingredient program ATR-COSF, and Apollomics and Faeth Therapeutics, both rising over 30% on no specific news.